JY
NVCT icon

Jeff Yass’s Nuvectis Pharma NVCT Stock Holding History

Jeff Yass’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
217,286
+112,000
+106% +$1.25M ﹤0.01% 5054
2026
Q1 		$814K Sell
105,286
-28,868
-22% -$247K ﹤0.01% 8429
2025
Q4 		$1.01M Buy
134,154
+43,275
+48% +$282K ﹤0.01% 7165
2025
Q3 		$547K Buy
90,879
+45,605
+101% +$313K ﹤0.01% 8744
2025
Q2 		$338K Buy
+45,274
New +$411K ﹤0.01% 10070
2025
Q1 		– Sell
-45,607
Closed -$328K – 13149
2024
Q4 		$247K Buy
45,607
+19,144
+72% +$120K ﹤0.01% 10242
2024
Q3 		$166K Buy
+26,463
New +$174K ﹤0.01% 10645
2024
Q1 		– Sell
-25,670
Closed -$214K – 12969
2023
Q4 		$214K Buy
+25,670
New +$229K ﹤0.01% 10542

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Jeff Yass's NVCT Position: Q2 2026 in Review

Jeff Yass increased its Nuvectis Pharma (NVCT) stake by 106% in Q2 2026, buying an estimated $1.25M and bringing the position to 217,286 shares worth $4M. The position accounts for ﹤0.01% of the portfolio, ranked #5054.

Jeff Yass first reported a position in NVCT in Q4 2023 and has held it in 8 quarters since. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Jeff Yass held 217,286 shares of Nuvectis Pharma worth $4M as of Q2 2026.
  • Jeff Yass bought 112,000 Nuvectis Pharma shares in Q2 2026, an estimated $1.25M.
  • Nuvectis Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5054 holding.
  • Jeff Yass first reported a position in Nuvectis Pharma in Q4 2023 and has held it in 8 quarters since.
  • 82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.